- Home
- VLGEA vs CRVS Comparison
VLGEA vs CRVS Comparison
Compare VLGEA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- CRVS
- Stock Information
- Founded
- VLGEA 1937
- CRVS 2014
- Country
- VLGEA United States
- CRVS United States
- Employees
- VLGEA N/A
- CRVS N/A
- Industry
- VLGEA Food Chains
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- CRVS Health Care
- Exchange
- VLGEA Nasdaq
- CRVS Nasdaq
- Market Cap
- VLGEA 491.9M
- CRVS 451.0M
- IPO Year
- VLGEA N/A
- CRVS 2016
- Fundamental
- Price
- VLGEA $32.38
- CRVS $8.95
- Analyst Decision
- VLGEA
- CRVS Buy
- Analyst Count
- VLGEA 0
- CRVS 4
- Target Price
- VLGEA N/A
- CRVS $12.83
- AVG Volume (30 Days)
- VLGEA 27.4K
- CRVS 1.0M
- Earning Date
- VLGEA 12-03-2024
- CRVS 11-12-2024
- Dividend Yield
- VLGEA 3.09%
- CRVS N/A
- EPS Growth
- VLGEA 0.45
- CRVS N/A
- EPS
- VLGEA 3.40
- CRVS N/A
- Revenue
- VLGEA $2,236,566,000.00
- CRVS N/A
- Revenue This Year
- VLGEA N/A
- CRVS N/A
- Revenue Next Year
- VLGEA N/A
- CRVS N/A
- P/E Ratio
- VLGEA $9.54
- CRVS N/A
- Revenue Growth
- VLGEA 3.23
- CRVS N/A
- 52 Week Low
- VLGEA $24.42
- CRVS $1.30
- 52 Week High
- VLGEA $33.99
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- VLGEA 56.71
- CRVS 60.45
- Support Level
- VLGEA $30.05
- CRVS $8.02
- Resistance Level
- VLGEA $33.24
- CRVS $8.71
- Average True Range (ATR)
- VLGEA 1.04
- CRVS 0.78
- MACD
- VLGEA -0.00
- CRVS -0.13
- Stochastic Oscillator
- VLGEA 69.04
- CRVS 52.70
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).